<DOC>
	<DOC>NCT01649804</DOC>
	<brief_summary>This extension study of WA19926 will assess the long-term safety and the efficacy of RoActemra/Actemra (tocilizumab) treatment in participants with rheumatoid arthritis. Participants who have completed the core study WA19926 are eligible to participate. Participants will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. The anticipated time on study drug is 104 weeks.</brief_summary>
	<brief_title>A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult participants, &gt;/=18 years of age who have completed the core study WA19926 and according to the investigator may benefit from RoActemra/Actemra treatment No current or recent adverse event or laboratory finding preventing the use of the study drug dose at baseline Receiving treatment on an outpatient basis Females who are pregnant Participants who have prematurely withdrawn from the core study WA19926 for any reason Treatment with any investigational drug since the last administration of the study drug in the core study WA19926 Treatment with an antitumor necrosis (TNF), antiinterleukin 1 agent or Tcell costimulation modulator since the last administration of the study drug in the core study WA19926 Immunization with live/attenuated vaccine since the last administration of the study drug in the core study WA19926 Diagnosis since the last WA19926 visit of rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis Abnormal laboratory values</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>